WallStreetZenWallStreetZen

NASDAQ: AMRX
Amneal Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for AMRX

Based on 3 analysts offering 12 month price targets for Amneal Pharmaceuticals Inc

Min Forecast
$15.00+9.33%
Avg Forecast
$17.00+23.91%
Max Forecast
$19.00+38.48%

Should I buy or sell AMRX stock?

Based on 3 analysts offering ratings for Amneal Pharmaceuticals Inc.

Strong Buy
Strong Buy
3 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Our proven Zen Rating quant model agrees with analyst consensus with a "Strong Buy" rating. Learn More

Be the first to know when Wall Street analysts revise their AMRX stock forecasts and price targets.

AMRX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-04-17
lockedlocked$00.00+00.00%2026-03-02
lockedlocked$00.00+00.00%2025-12-09Find Out Why

1 of 1

Forecast return on equity

Is AMRX forecast to generate an efficient return?

Company
-984.09%
Industry
16.12%
Market
152.93%
AMRX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is AMRX forecast to generate an efficient return on assets?

Company
12.62%
Industry
16.71%
AMRX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

AMRX earnings per share forecast

What is AMRX's earnings per share in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$1.01+158.92%
Avg 2 year Forecast
$1.20+207.56%
Avg 3 year Forecast
$1.40+259.18%
AMRX's earnings are forecast to... subscribe to Premium to read more.
Forecast High Earnings Growth Forecast

AMRX revenue forecast

What is AMRX's revenue in the next 3 years based on estimates from 7 analysts?

Avg 1 year Forecast
$3.2B+3.55%
Avg 2 year Forecast
$3.4B+10.94%
Avg 3 year Forecast
$3.6B+18.32%
AMRX's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

AMRX earnings growth forecast

How is AMRX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
75.64%
Industry
16.01%
Market
68.29%
AMRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
AMRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
AMRX's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

AMRX revenue growth forecast

How is AMRX forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
5.33%
Industry
8.07%
Market
16.77%
AMRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
AMRX's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

AMRX vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
AMRX$13.72$17.00+23.91%Strong Buy
INDV$39.60$48.00+21.21%Buy
SUPN$52.28$55.00+5.20%Hold
ALKS$35.40$45.67+29.00%Strong Buy
LNTH$91.00$92.67+1.83%Strong Buy
View Top Pharmaceutical Stocks

Amneal Pharmaceuticals Stock Forecast FAQ

Is Amneal Pharmaceuticals Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: AMRX) stock is to Strong Buy AMRX stock.

Out of 3 analysts, 3 (100%) are recommending AMRX as a Strong Buy, 0 (0%) are recommending AMRX as a Buy, 0 (0%) are recommending AMRX as a Hold, 0 (0%) are recommending AMRX as a Sell, and 0 (0%) are recommending AMRX as a Strong Sell.

If you're new to stock investing, here's how to buy Amneal Pharmaceuticals stock.

What is AMRX's earnings growth forecast for 2026-2028?

(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual earnings growth rate of 75.64% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 16.01%, and it is also forecast to beat the US market's average forecast earnings growth rate of 68.29%.

Amneal Pharmaceuticals's earnings in 2026 is $122,118,000.On average, 7 Wall Street analysts forecast AMRX's earnings for 2026 to be $322,149,215, with the lowest AMRX earnings forecast at $306,389,489, and the highest AMRX earnings forecast at $334,973,932. On average, 7 Wall Street analysts forecast AMRX's earnings for 2027 to be $382,667,839, with the lowest AMRX earnings forecast at $347,032,993, and the highest AMRX earnings forecast at $408,668,197.

In 2028, AMRX is forecast to generate $446,887,127 in earnings, with the lowest earnings forecast at $409,561,460 and the highest earnings forecast at $482,362,462.

What is AMRX's revenue growth forecast for 2026-2028?

(NASDAQ: AMRX) Amneal Pharmaceuticals's forecast annual revenue growth rate of 5.33% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.07%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 16.77%.

Amneal Pharmaceuticals's revenue in 2026 is $3,045,859,000.On average, 7 Wall Street analysts forecast AMRX's revenue for 2026 to be $1,006,197,885,968, with the lowest AMRX revenue forecast at $958,982,512,752, and the highest AMRX revenue forecast at $1,040,971,370,296. On average, 6 Wall Street analysts forecast AMRX's revenue for 2027 to be $1,077,978,014,168, with the lowest AMRX revenue forecast at $1,018,639,774,856, and the highest AMRX revenue forecast at $1,121,046,091,088.

In 2028, AMRX is forecast to generate $1,149,758,142,368 in revenue, with the lowest revenue forecast at $1,058,198,601,064 and the highest revenue forecast at $1,213,881,723,560.

What is AMRX's forecast return on assets (ROA) for 2026-2028?

(NASDAQ: AMRX) forecast ROA is 12.62%, which is lower than the forecast US Drug Manufacturers - Specialty & Generic industry average of 16.71%.

What is AMRX's Price Target?

According to 3 Wall Street analysts that have issued a 1 year AMRX price target, the average AMRX price target is $17.00, with the highest AMRX stock price forecast at $19.00 and the lowest AMRX stock price forecast at $15.00.

On average, Wall Street analysts predict that Amneal Pharmaceuticals's share price could reach $17.00 by Apr 17, 2027. The average Amneal Pharmaceuticals stock price prediction forecasts a potential upside of 23.91% from the current AMRX share price of $13.72.

What is AMRX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: AMRX) Amneal Pharmaceuticals's current Earnings Per Share (EPS) is $0.39. On average, analysts forecast that AMRX's EPS will be $1.01 for 2026, with the lowest EPS forecast at $0.96, and the highest EPS forecast at $1.05. On average, analysts forecast that AMRX's EPS will be $1.20 for 2027, with the lowest EPS forecast at $1.09, and the highest EPS forecast at $1.28. In 2028, AMRX's EPS is forecast to hit $1.40 (min: $1.28, max: $1.51).

What is AMRX's forecast return on equity (ROE) for 2026-2028?

(NASDAQ: AMRX) forecast ROE is -984.09%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.